CELLINK is the first bioink company in the world and the leading bioprinting technology provider. The company focuses on the development and commercialization of bioprinting technologies that allow researchers to 3D print human organs and tissues for the development of pharmaceutical and cosmetic products, and in the future, for clinical applications. CELLINK’s innovative and patent-pending bioink is a biomaterial innovation that enables human cells to grow and thrive as they would in the natural human body environment. Today, the company’s disruptive technology platform is being used to print tissues such as liver, cartilage, skin, and even fully functional cancer tumors that can then be used to develop new cancer treatments. The company has, within 12 months, commercialized products in more than 40 countries and sold to hundreds of prestigious labs around the world, such as Harvard, MIT, Princeton, and the FDA. Follow us on our journey to change the world of medicine.